China Post Securities: Maintains a "buy" rating for Sanon Healthcare (01530.HK), with multiple clinical trials accelerating the realization of global value.

Wisdom Finances App learned that China Post Securities released a research report stating that Sansheng Pharmaceuticals (01530.HK) is an established company in the domestic pharmaceutical field, with a number of cash cow varieties such as Tebipio, providing innovative input for research and development. The 707 authorizations have been implemented, increasing company profits while reducing the risk exposure in expanding into global markets. The bank predicts that the company's net profit attributable to shareholders will be 27.3/28.3/31.9 billion yuan from 2026 to 2028 (previous values: 24.1/27.6/- billion yuan), with year-on-year growth of 68%/+4%/+13%, corresponding to a PE ratio of 20/19/17, maintaining a "buy" rating.